-

Rebecca Lim (Prescient Therapeutics) Speaks On Cell Therapy's Latest R&D, Technologies & Challenges

281 Aufrufe

13.08.2021

8

0

TEILEN

SPEICHERN

IMAPAC Webcast

139 Abonnenten

ABONNIEREN

IMAPAC had the opportunity to sit down with Rebecca Lim (Director of Scientific Affairs, Prescient Therapeutics, Australia) to discuss the cell therapy industry's latest research & development, technologies and commercialization hurdles. 00:00 Introducing Rebecca Lim01:35 Q: Could you tell me more about your company, Prescient Therapeutics?02:05 Q: In your opinion, what are the key trends that you believe will shape the gene therapy industry moving forward in a post-pandemic world, especially in Asia? 03:48 Q: Are there any exciting technologies or developments that have caught your attention in the Year 2020/2021? 05:16 Q: What are the key challenges this industry faces and is currently trying to overcome?07:00 Q: How can regulations evolve to address these challenges?08:15 Q: What are the current struggles with respect to commercialization of gene therapies and how would you suggest they be overcome? 09:30 Q: What developments should the industry look out for from Prescient Therapeutics in the coming year? 10:55 Q: Name 2 things you are looking forward to at the Cell & Gene Therapy World Asia 2021 conference. 12:00 Q: What are some of the key takeaways the audience can expect from your presentation? She will also be presenting at the upcoming 5th Annual Cell & Gene Therapy World Asia, live streaming on 15th and 16th September 2021.Join her and many cell & gene therapy experts from around the world to discuss key themes surrounding CAR-T therapies, stem cell therapies, gene therapies and more. If you'd like to join the conversation, you may register here:For biopharmas & big pharmas with their own product pipelines: https://bit.ly/3ihnuQGFor CMO/CDMO/CROs and technology providers: https://bit.ly/3yl9JpL

-